Potential Anti-Coronavirus Agents and the Pharmacologic Mechanisms

References

• GorbalenyaAE, BakerSC, BaricRS, et al. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5(4):536–544.32123347
   PubMed Web of Science ®Google Scholar
• de WitE, van DoremalenN, FalzaranoD, MunsterVJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14(8):523–534. doi:10.1038/nrmicro.2016.8127344959
   PubMed Web of Science ®Google Scholar
• TuHL, TuS, GaoSQ, ShaoAW, ShengJF. Current epidemiological and clinical features of COVID-19; a global perspective from China. J Infect. 2020;81(1):1–9. doi:10.1016/j.jinf.2020.04.01132315723
   PubMed Web of Science ®Google Scholar
• ChanJFW, ZhuK-HK, ZhuZ. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan (vol 23, pg 2511, 2019). Emerg Microbes Infect. 2020;9(1):540.32133926
   PubMed Web of Science ®Google Scholar
• SkipperCP, PastickKA, EngenNW, et al. Hydroxychloroquine in nonhospitalized adults with early COVID-19: a randomized trial. Ann Intern Med. 2020. doi:10.7326/M20-4207
   PubMed Web of Science ®Google Scholar
• ZhuN, ZhangDY, WangWL, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733. doi:10.1056/NEJMoa200101731978945
   PubMed Web of Science ®Google Scholar
• LaiCC, LiuYH, WangCY, et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): facts and myths. J Microbiol Immunol Infect. 2020;53(3):404–412. doi:10.1016/j.jmii.2020.02.01232173241
   PubMedGoogle Scholar
• HoffmannM, Kleine-WeberH, SchroederS, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271. doi:10.1016/j.cell.2020.02.05232142651
   PubMed Web of Science ®Google Scholar
• RothanHA, ByrareddySN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433. doi:10.1016/j.jaut.2020.10243332113704
   PubMed Web of Science ®Google Scholar
• HuangC, WangY, LiX, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi:10.1016/S0140-6736(20)30183-531986264
   PubMed Web of Science ®Google Scholar
• ZumlaA, ChanJFW, AzharEI, HuiDSC, YuenKY. Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016;15(5):327–347.26868298
   PubMed Web of Science ®Google Scholar
• BelshawR, GardnerA, RarnbaUtA, PybusOG. Pacing a small cage: mutation and RNA viruses. Trends Ecol Evol. 2008;23(4):188–193. doi:10.1016/j.tree.2007.11.01018295930
   PubMed Web of Science ®Google Scholar
• FriemanMB, YountB, SimsAC, et al. SARS coronavirus accessory ORFs encode luxury functions. Adv Exp Med Biol. 2006;581:149–152.17037522
   PubMed Web of Science ®Google Scholar
• MenacheryVD, MitchellHD, CockrellAS, et al. MERS-CoV accessory ORFs play key role for infection and pathogenesis. mBio. 2017;8(4). doi:10.1128/mBio.00665-17.
   Web of Science ®Google Scholar
• LiuDX, FungTS, ChongKK, ShuklaA, HilgenfeldR. Accessory proteins of SARS-CoV and other coronaviruses. Antiviral Res. 2014;109:97–109. doi:10.1016/j.antiviral.2014.06.01324995382
   PubMed Web of Science ®Google Scholar
• SnijderEJ, van der MeerY, Zevenhoven-DobbeJ, et al. Ultrastructure and origin of membrane vesicles associated with the severe acute respiratory syndrome coronavirus replication complex. J Virol. 2006;80(12):5927–5940. doi:10.1128/JVI.02501-0516731931
   PubMed Web of Science ®Google Scholar
• van BoheemenS, de GraafM, LauberC, et al. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. mBio. 2012;3(6). doi:10.1128/mBio.00473-12.
   PubMed Web of Science ®Google Scholar
• ZiebuhrJ, SnijderEJ, GorbalenyaAE. Virus-encoded proteinases and proteolytic processing in the Nidovirales. J Gen Virol. 2000;81(Pt 4):853–879. doi:10.1099/0022-1317-81-4-85310725411
   PubMed Web of Science ®Google Scholar
• SturmanLS, HolmesKV. The molecular biology of coronaviruses. Adv Virus Res. 1983;28:35–112.6362367
   PubMed Web of Science ®Google Scholar
• da SilvaSJR. Role of nonstructural proteins in the pathogenesis of SARS-CoV-2. J Med Virol. 2020;92(9):1427–1429. doi:10.1016/j.jmii.2020.03.02232270884
   PubMed Web of Science ®Google Scholar
• WangQ, WuJ, WangH, et al. Structural basis for RNA Replication by the SARS-CoV-2 polymerase. Cell. 2020;182(2):417–428.e13. doi:10.1016/j.cell.2020.05.03432526208
   PubMed Web of Science ®Google Scholar
• ChenL, ZhongL. Genomics functional analysis and drug screening of SARS-CoV-2. Genes Dis. 2020;7(4):542–550. doi:10.1016/j.gendis.2020.04.00232363223
   PubMed Web of Science ®Google Scholar
• FinkelY, MizrahiO, NachshonA, et al. The coding capacity of SARS-CoV-2. Nature. 2020. doi:10.1038/s41586-020-2739-1
   Web of Science ®Google Scholar
• ChanJF, KokKH, ZhuZ, et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9(1):221–236. doi:10.1080/22221751.2020.171990231987001
   PubMed Web of Science ®Google Scholar
• MastersPS. The molecular biology of coronaviruses. In: MaramoroschK, ShatkinAJ, editors. Advances in Virus Research. Vol. 66. Elsevier Academic Press Inc; 2006:193.16877062
   PubMedGoogle Scholar
• DalyJL, SimonettiB, KleinK, et al. Neuropilin-1 is a host factor for SARS-CoV-2 infection. Science. 2020;370(6518):861–865. doi:10.1126/science.abd307233082294
   PubMed Web of Science ®Google Scholar
• FungTS, LiuDX. Human coronavirus: host-pathogen interaction. In: GottesmanS, editor. Annual Review of Microbiology. Vol. 73. 2019: 529–557.
   PubMed Web of Science ®Google Scholar
• SimmonsG, ReevesJD, RennekampAJ, AmbergSM, PieferAJ, BatesP. Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. Proc Natl Acad Sci U S A. 2004;101(12):4240–4245. doi:10.1073/pnas.030644610115010527
   PubMed Web of Science ®Google Scholar
• MilletJK, WhittakerGR. Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein. Proc Natl Acad Sci U S A. 2014;111(42):15214–15219. doi:10.1073/pnas.140708711125288733
   PubMed Web of Science ®Google Scholar
• CoutardB, ValleC, de LamballerieX, CanardB, SeidahNG, DecrolyE. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res. 2020;176(5):104742. doi:10.1016/j.antiviral.2020.10474232057769
   PubMed Web of Science ®Google Scholar
• ChenY, GuoY, PanYH, ZhaoZJ. Structure analysis of the receptor binding of 2019-nCoV. Biochem Biophys Res Commun. 2020;525(1):135–140. doi:10.1016/j.bbrc.2020.02.071
   PubMed Web of Science ®Google Scholar
• MilletJK, WhittakerGR. Host cell proteases: critical determinants of coronavirus tropism and pathogenesis. Virus Res. 2015;202:120–134. doi:10.1016/j.virusres.2014.11.02125445340
   PubMed Web of Science ®Google Scholar
• AlagailiAN, BrieseT, MishraN, et al. Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia. mBio. 2014;5(2):e00884–14. doi:10.1128/mBio.01002-1424570370
   PubMed Web of Science ®Google Scholar
• MackayIM, ArdenKE. MERS coronavirus: diagnostics, epidemiology and transmission. Virol J. 2015;12(1):222. doi:10.1186/s12985-015-0439-526695637
   PubMed Web of Science ®Google Scholar
• GeXY, LiJL, YangXL, et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature. 2013;503(7477):535–538. doi:10.1038/nature1271124172901
   PubMed Web of Science ®Google Scholar
• MenacheryVD, YountBL Jr, DebbinkK, et al. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat Med. 2015;21(12):1508–1513. doi:10.1038/nm.398526552008
   PubMed Web of Science ®Google Scholar
• SchoofM, FaustB, SaundersRA, et al. An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike. Science. 2020;370(6523):1473–1479.33154106
   PubMed Web of Science ®Google Scholar
• AngeliniMM, AkhlaghpourM, NeumanBW, BuchmeierMJ, MosconaA. Severe acute respiratory syndrome coronavirus nonstructural proteins 3, 4, and 6 induce double-membrane vesicles. mBio. 2013;4(4). doi:10.1128/mBio.00524-13
   PubMed Web of Science ®Google Scholar
• MaierHJ, HawesPC, CottamEM, et al. Infectious bronchitis virus generates spherules from zippered endoplasmic reticulum membranes. mBio. 2013;4(5):e00801–13. doi:10.1128/mBio.00801-1324149513
   PubMed Web of Science ®Google Scholar
• LundinA, DijkmanR, BergstromT, et al. Targeting membrane-bound viral RNA synthesis reveals potent inhibition of diverse coronaviruses including the Middle East respiratory syndrome virus. PLoS Pathog. 2014;10(5):e1004166. doi:10.1371/journal.ppat.100416624874215
   PubMed Web of Science ®Google Scholar
• LaiMM, CavanaghD. The molecular biology of coronaviruses. Adv Virus Res. 1997;48:1–100.9233431
   PubMed Web of Science ®Google Scholar
• KlumpermanJ, LockerJK, MeijerA, HorzinekMC, GeuzeHJ, RottierPJ. Coronavirus M proteins accumulate in the Golgi complex beyond the site of virion budding. J Virol. 1994;68(10):6523–6534. doi:10.1128/JVI.68.10.6523-6534.19948083990
   PubMed Web of Science ®Google Scholar
• RuchTR, MachamerCE. The coronavirus E protein: assembly and beyond. Viruses. 2012;4(3):363–382. doi:10.3390/v403036322590676
   PubMed Web of Science ®Google Scholar
• EleouetJF, SleeEA, SauriniF, et al. The viral nucleocapsid protein of transmissible gastroenteritis coronavirus (TGEV) is cleaved by caspase-6 and −7 during TGEV-induced apoptosis. J Virol. 2000;74(9):3975–3983. doi:10.1128/JVI.74.9.3975-3983.200010756009
   PubMed Web of Science ®Google Scholar
• ZunigaS, SolaI, MorenoJL, SabellaP, Plana-DuranJ, EnjuanesL. Coronavirus nucleocapsid protein is an RNA chaperone. Virology. 2007;357(2):215–227. doi:10.1016/j.virol.2006.07.04616979208
   PubMed Web of Science ®Google Scholar
• WangJ, DuG. COVID-19 may transmit through aerosol. Ir J Med Sci. 2020. doi:10.1007/s11845-020-02218-2
   Web of Science ®Google Scholar
• ZouL, RuanF, HuangM, et al. SARS-CoV-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020;382(12):1177–1179. doi:10.1056/NEJMc200173732074444
   PubMed Web of Science ®Google Scholar
• XiaoF, TangM, ZhengX, LiuY, LiX, ShanH. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology. 2020;158(6):1831–1833 e3. doi:10.1053/j.gastro.2020.02.05532142773
   PubMed Web of Science ®Google Scholar
• DingY, WangH, ShenH, et al. The clinical pathology of severe acute respiratory syndrome (SARS): a report from China. J Pathol. 2003;200(3):282–289. doi:10.1002/path.144012845623
   PubMed Web of Science ®Google Scholar
• NgDL, Al HosaniF, KeatingMK, et al. Clinicopathologic, immunohistochemical, and ultrastructural findings of a fatal case of middle east respiratory syndrome coronavirus infection in the united arab emirates, April 2014. Am J Pathol. 2016;186(3):652–658. doi:10.1016/j.ajpath.2015.10.02426857507
   PubMed Web of Science ®Google Scholar
• GuanWJ, NiZY, HuY, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720. doi:10.1056/NEJMoa200203232109013
   PubMed Web of Science ®Google Scholar
• XuZ, ShiL, WangY, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420–422. doi:10.1016/S2213-2600(20)30076-X32085846
   PubMed Web of Science ®Google Scholar
• ZouX, ChenK, ZouJ, HanP, HaoJ, HanZ. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med. 2020;14(2):185–192. doi:10.1007/s11684-020-0754-032170560
   PubMed Web of Science ®Google Scholar
• RizzoP, Vieceli Dalla SegaF, FortiniF, MarracinoL, RapezziC, FerrariR. COVID-19 in the heart and the lungs: could we “Notch” the inflammatory storm? Basic Res Cardiol. 2020;115(3). doi:10.1007/s00395-020-0791-5
   PubMed Web of Science ®Google Scholar
• YeQ, WangB, MaoJ. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J Infect. 2020;80(6):607–613. doi:10.1016/j.jinf.2020.03.03732283152
   PubMed Web of Science ®Google Scholar
• ChenY, LiuQ, GuoD. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol. 2020;92(4):418–423. doi:10.1002/jmv.2568131967327
   PubMed Web of Science ®Google Scholar
• ChanJF, YuanS, KokKH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514–523. doi:10.1016/S0140-6736(20)30154-931986261
   PubMed Web of Science ®Google Scholar
• WangD, HuB, HuC, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–1069. doi:10.1001/jama.2020.158532031570
   PubMed Web of Science ®Google Scholar
• LiuJ, ZhengX, TongQ, et al. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV. J Med Virol. 2020;92(5):491–494. doi:10.1002/jmv.2570932056249
   PubMed Web of Science ®Google Scholar
• JinY, YangH, JiW, et al. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses. 2020;12(4):4. doi:10.3390/v12040372
   Web of Science ®Google Scholar
• MousavizadehL, GhasemiS. Genotype and phenotype of COVID-19: their roles in pathogenesis. J Microbiol Immunol Infect. 2020.
   PubMedGoogle Scholar
• Nikolich-ZugichJ, KnoxKS, RiosCT, NattB, BhattacharyaD, FainMJ. SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes. Geroscience. 2020;42(2):505–514. doi:10.1007/s11357-020-00186-032274617
   PubMed Web of Science ®Google Scholar
• BadenLR, RubinEJ. Covid-19 - the search for effective therapy. N Engl J Med. 2020;382(19):1851–1852. doi:10.1056/NEJMe200547732187463
   PubMed Web of Science ®Google Scholar
• LiG, De ClercqE. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020;19(3):149–150. doi:10.1038/d41573-020-00016-032127666
   PubMed Web of Science ®Google Scholar
• DalerbaP, LevinB, ThompsonJL. A trial of lopinavir–ritonavir in Covid-19. N Engl J Med. 2020.
   PubMedGoogle Scholar
• HungIF-N, LungK-C, TsoEY-K, et al. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, Phase 2 trial. Lancet. 2020. doi:10.1016/S0140-6736(20)31042-4
   Web of Science ®Google Scholar
• CaoB, WangY, WenD, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787–1799. doi:10.1056/NEJMoa200128232187464
   PubMed Web of Science ®Google Scholar
• WangM, CaoR, ZhangL, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–271. doi:10.1038/s41422-020-0282-032020029
   PubMed Web of Science ®Google Scholar
• AgostiniML, AndresEL, SimsAC, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio. 2018;9(2). doi:10.1128/mBio.00221-18.
   PubMed Web of Science ®Google Scholar
• GreinJ, OhmagariN, ShinD, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020. doi:10.1056/NEJMoa2007016
   Web of Science ®Google Scholar
• WangY, ZhangD, DuG, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569–1578. doi:10.1016/S0140-6736(20)31022-932423584
   PubMed Web of Science ®Google Scholar
• ShannonA, SeliskoB, LeNT, et al. Rapid incorporation of favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis. Nat Commun. 2020;11(1):4682. doi:10.1038/s41467-020-18463-z32943628
   PubMed Web of Science ®Google Scholar
• RobsonF, KhanKS, LeTK, et al. Coronavirus RNA proofreading: molecular basis and therapeutic targeting. Mol Cell. 2020;79(5):710–727. doi:10.1016/j.molcel.2020.07.02732853546
   PubMed Web of Science ®Google Scholar
• KapteinSJF, JacobsS, LangendriesL, et al. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity. Proc Natl Acad Sci U S A. 2020;117(43):26955–26965. doi:10.1073/pnas.201444111733037151
   PubMed Web of Science ®Google Scholar
• IvashchenkoAA, DmitrievKA, VostokovaNV, et al. AVIFAVIR for treatment of patients with moderate COVID-19: interim results of a phase II/III multicenter randomized clinical trial. Clin Infect Dis. 2020.
   Google Scholar
• JácomeR, Campillo-BalderasJA, Ponce de LeónS, BecerraA, LazcanoA. Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic. Sci Rep. 2020;10(1):9294. doi:10.1038/s41598-020-66440-932518317
   PubMed Web of Science ®Google Scholar
• ChienM, AndersonTK, JockuschS, et al. Nucleotide analogues as inhibitors of SARS-CoV-2 polymerase, a key drug target for COVID-19. J Proteome Res. 2020;19(11):4690–4697. doi:10.1021/acs.jproteome.0c0039232692185
   PubMed Web of Science ®Google Scholar
• BeckBR, ShinB, ChoiY, ParkS, KangK. Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model. Comput Struct Biotechnol J. 2020;18:784–790. doi:10.1016/j.csbj.2020.03.02532280433
   PubMed Web of Science ®Google Scholar
• RoozbehF, SaeediM, Alizadeh-NavaeiR, et al. Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial. J Antimicrob Chemother. 2020.
   Web of Science ®Google Scholar
• SadeghiA, Ali AsgariA, NorouziA, et al. Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial. J Antimicrob Chemother. 2020;75(11):3379–3385. doi:10.1093/jac/dkaa33432812039
   PubMed Web of Science ®Google Scholar
• EslamiG, MousaviaslS, RadmaneshE, et al. The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19. J Antimicrob Chemother. 2020;75(11):3366–3372. doi:10.1093/jac/dkaa33132812051
   PubMed Web of Science ®Google Scholar
• FuY, ChengY, WuY. Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools. Virol Sin. 2020;35(3):266–271. doi:10.1007/s12250-020-00207-432125642
   PubMed Web of Science ®Google Scholar
• AzizM, FatimaR, AssalyR. Elevated interleukin-6 and severe COVID-19: a meta-analysis. J Med Virol. 2020;92(11):2283–2285. doi:10.1002/jmv.2594832343429
   PubMed Web of Science ®Google Scholar
• ZhuJ, PangJ, JiP, et al. Elevated interleukin-6 is associated with severity of COVID-19: a meta-analysis. J Med Virol. 2020.
   Web of Science ®Google Scholar
• HeroldT, JurinovicV, ArnreichC, et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J Allergy Clin Immunol. 2020;146(1):128–136.e4. doi:10.1016/j.jaci.2020.05.00832425269
   PubMed Web of Science ®Google Scholar
• XuX, HanM, LiT, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020;117(20):10970–10975. doi:10.1073/pnas.200561511732350134
   PubMed Web of Science ®Google Scholar
• MorrisonAR, JohnsonJM, GriebeKM, et al. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab. J Autoimmun. 2020;114:102512. doi:10.1016/j.jaut.2020.10251232646770
   PubMed Web of Science ®Google Scholar
• GuptaS, WangW, HayekSS, et al. Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19. JAMA Intern Med. 2020.
   Web of Science ®Google Scholar
• SalamaC, HanJ, YauL, et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2020. doi:10.1056/NEJMoa2030340
   PubMed Web of Science ®Google Scholar
• SalvaraniC, DolciG, MassariM, et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. JAMA Intern Med. 2020.
   Web of Science ®Google Scholar
• HermineO, MarietteX, TharauxPL, Resche-RigonM, PorcherR, RavaudP. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern Med. 2020.
   Web of Science ®Google Scholar
• KonoM, TatsumiK, ImaiAM, SaitoK, KuriyamaT, ShirasawaH. Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: involvement of p38 MAPK and ERK. Antiviral Res. 2008;77(2):150–152. doi:10.1016/j.antiviral.2007.10.01118055026
   PubMed Web of Science ®Google Scholar
• HashemAM, AlghamdiBS, AlgaissiAA, et al. Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: a narrative review. Travel Med Infect Dis. 2020. doi:10.1016/j.tmaid.2020.101735
   PubMed Web of Science ®Google Scholar
• SavarinoA, BoelaertJR, CassoneA, MajoriG, CaudaR. Effects of chloroquine on viral infections: an old drug against today’s diseases. Lancet Infect Dis. 2003;3(11):722–727. doi:10.1016/S1473-3099(03)00806-514592603
   PubMed Web of Science ®Google Scholar
• DevauxCA, RolainJM, ColsonP, RaoultD. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020;105938.
   Google Scholar
• ZhaoM. Cytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies. Int J Antimicrob Agents. 2020. doi:10.1016/j.ijantimicag.2020.105982
   Web of Science ®Google Scholar
• LiX, GengM, PengY, MengL, LuS. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. 2020;10(2):102–108. doi:10.1016/j.jpha.2020.03.00132282863
   PubMed Web of Science ®Google Scholar
• GautretP, LagierJC, ParolaP, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1):105949. doi:10.1016/j.ijantimicag.2020.10594932205204
   PubMed Web of Science ®Google Scholar
• MolinaJM, DelaugerreC, Le GoffJ, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect. 2020;50(4):384. doi:10.1016/j.medmal.2020.03.00632240719
   PubMed Web of Science ®Google Scholar
• SharmaA. Chloroquine paradox may cause more damage than help fight COVID-19. Microb Infect. 2020;22(4–5):154–156. doi:10.1016/j.micinf.2020.04.004
   PubMed Web of Science ®Google Scholar